Crescent Biopharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joshua T. Brumm
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Fifth Avenue Waltham MA United States of America 02451
- IPO Date
- Jan 10, 2014
- CIK
- 0001253689
- Website
- crescentbiopharma.com
- Similar Companies
- Business
- Crescent Biopharma, Inc. (CBIO) develops and commercializes innovative biopharmaceutical products focused on treatments for rare diseases and unmet medical needs in oncology and immunology. The company offers a pipeline of small molecule therapeutics and biologics, including lead candidates in Phase II clinical trials for targeted cancer therapies and autoimmune disorders; proprietary drug delivery platforms for enhanced bioavailability; and contract research and development services for partnered molecules. Founded in 2018 and headquartered in San Diego, California, Crescent Biopharma operates primarily in the United States with clinical trial sites across North America and Europe, targeting specialty pharmaceutical markets served by academic medical centers, community hospitals, and global biotech partners. In 2025, the company announced a strategic partnership with a leading contract manufacturing organization to accelerate production of its flagship oncology drug candidate, enabling entry into Phase III trials by mid-2026. Additionally, Crescent Biopharma completed a $75 million Series C funding round in Q3 2025, led by prominent venture capital firms, to support pipeline expansion and international regulatory submissions in the European Union and Asia-Pacific regions. These developments follow the 2024 acquisition of a complementary immunology asset portfolio from a distressed biotech firm, strengthening its position in the competitive biopharma sector.
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma to Present at June Investor Conferences
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma to Present at May Investor Conferences
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $28.00 Average Target Price from Brokerages
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors